2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
15
Prostatic Neoplasms
11
Osteoporosis
6
Neoplasms
4
Melanoma
3
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Cardiovascular Diseases
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Unspecified Childhood Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Sarcoma, Ewing
1
Regional Osteoporosis as a Result of Chemotherapy
1
Recurrence
1
Primary Ovarian Insufficiency
1
Polycystic Ovary Syndrome
1
Paraganglioma, Extra-Adrenal
1
Pain
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Monoclonal Gammopathy of Undetermined Significance
1
Interventions
pembrolizumab
92
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
26
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Absorptiometry, Photon
×
Clear all
NCT01490437
2014-09-25
PECULIAR
Asan Medical Center
Phase 2
Completed
42 enrolled